• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ERYTHROMYCIN Drug Record

  • Summary
  • Interactions
  • Claims
  • ERYTHROMYCIN chembl:CHEMBL532 Approved

    Alternate Names:

    NSC-55929
    E-GLADES
    ERYC
    PAEDIATHROCIN
    ERYGEL
    E-SOLVE 2
    E-MYCIN
    ERYDERM
    A/T/S
    C-SOLVE-2
    J01FA01
    OFTALMOLOSA CUSI ERITROMICINA
    WYAMYCIN
    STIEMYCIN
    ERYTHROCIN
    KERYMAX
    ZINERYT
    SANSAC
    AKNEMYCIN PLUS
    ERYACNE 2
    ERYMAX
    STATICIN
    EMGEL
    ERYACNE 4
    R-P MYCIN
    AKNE-MYCIN
    ERY-TAB
    BRISTAMYCIN
    ROMMIX 250 EC
    ROBIMYCIN
    ERYTHRO 200
    ERYPAR
    ERYC 125
    ERYC SPRINKLES
    ERYTHROMYCIN
    ERYCETTE
    ERYTHRO-STATIN
    TILORYTH
    ERYTHRA-DERM
    ILOTYCIN
    PCE
    GALLIMYCIN
    T-STAT
    ROMMIX 500 EC
    ERYMAX SPRINKLE
    RETCIN
    E-BASE
    PFIZER-E
    BENZAMYCIN
    ISOTREXIN
    ÉRYTHROMYCINE
    (2R,4S,5R,8R,12R,14R)-11-[(3R,4S,6R)-4-(DIMETHYLAMINO)-3-HYDROXY-6-METHYL-OXAN-2-YL]OXY-5-ETHYL-3,4,12-TRIHYDROXY-9-[(2R,4R,5S,6S)-5-HYDROXY-4-METHOXY-4,6-DIMETHYL-OXAN-2-YL]OXY-2,4,8,10,12,14-HEXAMETHYL-6-OXACYCLOTETRADECANE-1,7-DIONE
    6-(4-DIMETHYLAMINO-3-HYDROXY-6-METHYL-TETRAHYDRO-PYRAN-2-YLOXY)-14-ETHYL-7,12,13-TRIHYDROXY-4-(5-HYDROXY-4-METHOXY-4,6-DIMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-3,5,7,9,11,13-HEXAMETHYL-OXACYCLOTETRADECANE-2,10-DIONE(ERYTHROMYCIN)
    ERYTHROMYCIN A
    (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(4-DIMETHYLAMINO-3-HYDROXY-6-METHYL-TETRAHYDRO-PYRAN-2-YLOXY)-14-ETHYL-7,12,13-TRIHYDROXY-4-(5-HYDROXY-4-METHOXY-4,6-DIMETHYL-TETRAHYDRO-PYRAN-2-YLOXY)-3,5,7,9,11,13-HEXAMETHYL-OXACYCLOTETRADECANE-2,10-DIONE
    ERYTHROMYCINUM
    ERITROMICINA
    ERYTHROMYCIN C
    ABOMACETIN
    ERTHROMYCIN
    3''-O-DEMETHYLERYTHROMYCIN
    (2R,4S,5R,8R,12R,14R)-11-[(3R,4S,6R)-4-(DIMETHYLAMINO)-3-HYDROXY-6-METHYLOXAN-2-YL]OXY-5-ETHYL-3,4,12-TRIHYDROXY-9-[(2R,4R,5S,6S)-5-HYDROXY-4-METHOXY-4,6-DIMETHYLOXAN-2-YL]OXY-2,4,8,10,12,14-HEXAMETHYL-6-OXACYCLOTETRADECANE-1,7-DIONE
    ERYTHROMYCINE
    rxcui:4053
    chemidplus:114-07-8
    drugbank:00199
    chembl:CHEMBL532
    pubchem.compound:12560

    Drug Info:

    (2 More Sources)

    Publications:

    Tsuda et al., 2008, Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes., Antimicrob. Agents Chemother.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Xu et al., 2006, [Effect of erythromycin on apoptosis of epithelial cell in nasal polyps]., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi
    Takeshita et al., 1989, Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages., Drugs Exp Clin Res
    Terashi et al., 2000, Interactions of ofloxacin and erythromycin with the multidrug resistance protein (MRP) in MRP-overexpressing human leukemia cells., Antimicrob. Agents Chemother.
    Volberg et al., 2002, Blockade of human cardiac potassium channel human ether-a-go-go-related gene (HERG) by macrolide antibiotics., J. Pharmacol. Exp. Ther.
    Stanat et al., 2003, Characterization of the inhibitory effects of erythromycin and clarithromycin on the HERG potassium channel., Mol. Cell. Biochem.
    Du et al., 2004, The pharmacophore hypotheses of I(Kr) potassium channel blockers: novel class III antiarrhythmic agents., Bioorg. Med. Chem. Lett.
    Wisialowski T et al., 2006, Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability., J Pharmacol Exp Ther
    Crumb WJ Jr, 2014, Allosteric effects of erythromycin pretreatment on thioridazine block of hERG potassium channels., Br J Pharmacol
    Vanaudenaerde et al., 2007, Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells., Am. J. Transplant.
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev
    Elens L et al., 2013, CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin., Pharmacogenomics
    Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos
    Aktan et al., Effect of macrolide antibiotics on nitric oxide synthase and xanthine oxidase activities, and malondialdehyde level in erythrocyte of the guinea pigs with experimental otitis media with effusion., Pol J Pharmacol
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
  • ERYTHROMYCIN   F2RL1

    Interaction Score: 0.81

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18212111


    Sources:
    DTC

  • ERYTHROMYCIN   IL17A

    Interaction Score: 0.41

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17061983


    Sources:
    NCI

  • ERYTHROMYCIN   XDH

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    14730107


    Sources:
    NCI

  • ERYTHROMYCIN   IL1B

    Interaction Score: 0.18

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    2534682


    Sources:
    NCI

  • ERYTHROMYCIN   BCL2

    Interaction Score: 0.15

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17007374


    Sources:
    NCI

  • ERYTHROMYCIN   BAX

    Interaction Score: 0.14

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17007374


    Sources:
    NCI

  • ERYTHROMYCIN   ABCC1

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    10817732


    Sources:
    NCI

  • ERYTHROMYCIN   CYP3A5

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18695978


    Sources:
    PharmGKB

  • ERYTHROMYCIN   ABCC2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ERYTHROMYCIN   KCNH2

    Interaction Score: 0.06

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    12065733 14674677 15324906 16614168 24417241


    Sources:
    PharmGKB

  • ERYTHROMYCIN   G6PD

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:
    Combination therapy Erythromycin,Sulfisoxazole

    PMIDs:
    None found


    Sources:
    FDA

  • ERYTHROMYCIN   NR1I2

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ERYTHROMYCIN   PLK1

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • ERYTHROMYCIN   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9187528 23327575 21393461


    Sources:
    DTC PharmGKB

  • ERYTHROMYCIN   CYP2C9

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ERYTHROMYCIN   CYP2C19

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ERYTHROMYCIN   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ERYTHROMYCIN   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • ERYTHROMYCIN   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • DTC: ERYTHROMYCIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL532 ChEMBL Drug ID

    Drug Info:

    Publications:
    Tsuda et al., 2008, Effect of 14-membered-ring macrolides on production of interleukin-8 mediated by protease-activated receptor 2 in human keratinocytes., Antimicrob. Agents Chemother.
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Li P et al., 2011, A refined cytochrome P540 IC₅₀ shift assay for reliably identifying CYP3A time-dependent inhibitors., Drug Metab Dispos

  • NCI: ERYTHROMYCIN

    • Version: 14-September-2017

    Alternate Names:
    C476 NCI drug code

    Drug Info:

    Publications:
    Takeshita et al., 1989, Immunological and anti-inflammatory effects of clarithromycin: inhibition of interleukin 1 production of murine peritoneal macrophages., Drugs Exp Clin Res
    Vanaudenaerde et al., 2007, Macrolides inhibit IL17-induced IL8 and 8-isoprostane release from human airway smooth muscle cells., Am. J. Transplant.
    Xu et al., 2006, [Effect of erythromycin on apoptosis of epithelial cell in nasal polyps]., Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi

  • PharmGKB: erythromycin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Wisialowski T et al., 2006, Differentiation of arrhythmia risk of the antibacterials moxifloxacin, erythromycin, and telithromycin based on analysis of monophasic action potential duration alternans and cardiac instability., J Pharmacol Exp Ther
    Rendic S et al., 1997, Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors., Drug Metab Rev

  • TTD: Erythromycin

    • Version: 2020.06.01

    Alternate Names:
    D02YIZ TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL532

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

  • FDA: Erythromycin

    • Version: 04-September-2020

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21